Log in

NASDAQ:FLXN - Flexion Therapeutics Stock Price, Forecast & News

$20.79
-0.16 (-0.76 %)
(As of 12/12/2019 04:26 AM ET)
Today's Range
$20.51
Now: $20.79
$21.14
50-Day Range
$15.01
MA: $17.17
$21.01
52-Week Range
$8.76
Now: $20.79
$21.14
Volume666,625 shs
Average Volume632,285 shs
Market Capitalization$793.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.52 million
Book Value$2.91 per share

Profitability

Net Income$-169,660,000.00
Net Margins-266.51%

Miscellaneous

Employees272
Market Cap$793.66 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.


Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics Inc (NASDAQ:FLXN) released its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.01. The specialty pharmaceutical company earned $21.79 million during the quarter, compared to analysts' expectations of $18.85 million. Flexion Therapeutics had a negative net margin of 266.51% and a negative return on equity of 271.22%. View Flexion Therapeutics' Earnings History.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Flexion Therapeutics.

What price target have analysts set for FLXN?

9 brokers have issued 12 month target prices for Flexion Therapeutics' shares. Their forecasts range from $18.00 to $36.00. On average, they anticipate Flexion Therapeutics' share price to reach $25.50 in the next year. This suggests a possible upside of 22.7% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

What is the consensus analysts' recommendation for Flexion Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

What are Wall Street analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:
  • 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (12/10/2019)
  • 2. Northland Securities analysts commented, "We believe Zilretta’s superior safety and efficacy vs. IR-corticosteroids will make it the intra-articular injection of choice for treating OAK and other indications. We anticipate approval of the sNDA for repeat administration for OAK in mid-October. This, along w/ Zilretta receipt of J code (J3304) effective Co.’s pursuit of additional indications, i.e., hip and shoulder, we believe will support peak US sales >$750MM. Flexion reported 4Q Zilretta sales of $9.5MM, aligned w/ consensus. R&D and SG&A expense line items for the 4Q period totaled $14.9MM and $30.6MM, respectively, w/ EPS for the 4Q period at ($1.07) vs. the ($1.15) consensus." (3/1/2019)

Has Flexion Therapeutics been receiving favorable news coverage?

Media coverage about FLXN stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Flexion Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Flexion Therapeutics.

Are investors shorting Flexion Therapeutics?

Flexion Therapeutics saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 6,970,000 shares, a decline of 11.9% from the November 14th total of 7,910,000 shares. Based on an average daily trading volume, of 652,900 shares, the days-to-cover ratio is currently 10.7 days. Approximately 21.9% of the company's stock are short sold. View Flexion Therapeutics' Current Options Chain.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Cara Therapeutics (CARA), Verastem (VSTM), Celgene (CELG), Omeros (OMER), AcelRx Pharmaceuticals (ACRX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Neil Bodick, Co-Founder & Chief Scientific Officer (Age 72)
  • Mr. Mark S. Levine, Gen. Counsel & Sec. (Age 46)
  • Mr. David A. Arkowitz, Chief Financial Officer (Age 58)
  • Scott Young, VP of Corp. Communications & Investor Relations

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.88%), Peregrine Capital Management LLC (2.05%), Gilder Gagnon Howe & Co. LLC (1.31%), Selz Capital LLC (0.89%), SG Americas Securities LLC (0.40%) and Campbell Capital Management Inc. (0.34%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Gilder Gagnon Howe & Co. LLC, Selz Capital LLC, Voloridge Investment Management LLC and Cutler Group LP. Company insiders that have sold Flexion Therapeutics company stock in the last year include David Arkowitz, Mark S Levine and Michael D Clayman. View Insider Buying and Selling for Flexion Therapeutics.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Public Employees Retirement System of Ohio, Peregrine Capital Management LLC, Virtu Financial LLC, Millennium Management LLC, California Public Employees Retirement System, Commonwealth Equity Services LLC and Rhumbline Advisers. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $20.79.

How big of a company is Flexion Therapeutics?

Flexion Therapeutics has a market capitalization of $793.66 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  505 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  820
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel